Coagulation and bleeding disorders: Review and update

Clinical Chemistry

Volumn 46, Issue 8 II, 2000, Pages 1260-1269

  Triplett, D A ^a  

^a BALL MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETAMIDO] N [(3,5 DIMETHYL 4 ISOXAZOLYL)SULFONYL]ALANINE; 3 [[4 [4 [AMINO(ETHOXYCARBONYLIMINO)METHYL]PHENYL] 2 THIAZOLYL](1 ETHOXYCARBONYLMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID ETHYL ESTER; ABCIXIMAB; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DESMOPRESSIN; ECHISTATIN; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; HIGH MOLECULAR WEIGHT KININOGEN; KISTRIN; LAMIFIBAN; PREKALLIKREIN; PROTHROMBIN; RECOMBINANT ERYTHROPOIETIN; TIROFIBAN; XEMILOFIBAN;

ARACHIDONIC ACID METABOLISM; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; CONFERENCE PAPER; DISSEMINATED INTRAVASCULAR CLOTTING; HEMOSTASIS; HUMAN; PATHOGENESIS; THROMBOCYTE ANOMALY; THROMBOCYTE FUNCTION;

EID: 0033887427     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/46.8.1260     Document Type: Conference Paper

References (83)

1. Ultrastructural features of abnormal platelets
2. Congenital disorders of platelet function: Disorders of signal transduction and secretion
3. Biochemical mechanisms of platelet activation
4. Calcium signaling in human platelets
5. The clinical impact of platelet function testing
6. Molecular mechanisms of platelet adhesion and activation
7. Mechanisms of platelet activation and inhibition
8. Endothelial cells in physiology and in the pathophysiology of vascular disorders
9. The glycoprotein Ib-IX-V complex in platelet adhesion and signaling
10. Platelets and factor XI bypass the contact system of coagulation
11. Idiopathic thrombocytopenic purpura: Diagnosis and management
12. Measurement of the bleeding time
13. A critical reappraisal of the bleeding time
14. Bleeding in renal failure [Review]
15. Uremic bleeding: Pathogenesis and therapy
16. Improvement of the haemostatic defect of uraemia after treatment with recombinant human erythropoietin
17. Natural history of Ehlers-Danlos syndrome type IV (EDS type IV): Review of 137 cases
18. Zur beurteilung des rumpel-leedeschen scharlacy-phanomens
19. Aggregation of blood platelets by adenosine diphosphate and its reversal
20. Sources of variability in dose response platelet aggregometry
21. Inherited disorders of platelets α granules
22. Inherited platelet disorders
23. Hermansky-Pudlak syndrome in a Swiss population
24. The Chediak Higashi syndrome: CT and MR findings
25. Adult Chediak-Higashi syndrome presenting as parkinsonism and dementia
26. Antenatal thrombocylopenia in three individuals with TAR (thrombocytopenia with absent radii) syndrome
27. Glanzmann's thrombasthenia
28. Identification of a new congenital defect of platelet function characterized by several impairment of platelet response to adenosine diphosphate
29. Differential requirements for epinephrine induced platelet aggregation and inhibition of adenylate cyclase
30. Human blood platelets showing no response to collagen fail to express surface glycoprotein la
31. Platelet glycoprotein IIb/IIIa inhibitors
32. The prothrombin consumption test: Its clinical and theoretic implications
33. In vitro assessment of platelet function
34. Flow cytometric analysis of platelet surface glycoproteins in the diagnosis of Bernard-Soulier syndrome
35. Measurement of platelet activation by fluorescence-activated flow cytometry
36. Xylum CSA®: Automated system for assessing hemostasis in simulated vascular flow
37. Coagulation of flowing native blood: Advantages over stagnant (tube) clotting tests
38. The platelet function analyzer (PFA-100®): A novel in vitro system for evaluation of primary hemostasis in children
39. The effect of antiplatelet drugs, heparin and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100®)
40. Description of an in vitro platelet function analyzer - PFA-100
41. Platelet GPIIb-IIIa blockers
42. Screening for von Willebrand disease with a new analyzer using high sheer stress: A study of 60 cases
43. Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia
44. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years
45. Effect of recombinant human erythropoietin on platelet production in dialysis patients
46. Uremic bleeding: Role of anemia and beneficial effect of red blood cell transfusions
47. An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier
48. Tissue factor and hemostasis
49. A membrane mediated catalytic event in prothrombin activation
50. Biochemistry and physiology of blood coagulation
51. The purification and mechanism of action of human antithrombin heparin cofactor
52. A catalytic role for heparin
53. A new member of the plasma protease inhibitor gene family
54. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis
55. The protein C pathway: New insights
56. Sensitivity of the activated partial thromboplastin time: Results of the CAP survey and a series of mild and moderate factor deficiencies
57. Prothrombin time standardization report of the Expert Panel on Oral Anticoagulant Control
58. A study of the plasma thrombin time
59. Experience with a thrombin clotting time assay for measuring heparin activity
60. An evaluation of currently available methods for plasma fibrinogen
61. The use of D-dimer testing and impedance plethysmographic examination in patients with clinical indications of deep vein thrombosis
62. Screening for the lupus anticoagulant
63. Report of the working party on acquired inhibitors of coagulation: Studies on the 'lupus' anticoagulant
64. Acquired hemophilia
65. A survey of 215 non-hemophilic patients with inhibitors to factor VIII
66. Confusion over the therapeutic range for monitoring oral anticoagulant therapy in North America
67. Oral anticoagulants: Mechanism of action, clinical effectiveness and optimal therapeutic range
68. Von Willebrand disease: Pathogenesis, classification, and management
69. Females with von Willebrand disease: 72 years as the silent majority
70. Von Willebrand disease
71. Von Willebrand disease in children and adolescents
72. Von Willebrand disease: Recent advances in pathophysiology and treatment
73. Laboratory diagnosis of Von Willebrand's disease
74. Molecular genetics of Von Willebrand disease
75. Three cases of acquired von Willebrand disease associated with systemic lupus erythematosus
76. Historical review: The history of haemophilia in the royal families of Europe
77. The hemophilias: Progress and problems
78. The manufacturing of recombinant factor VIII, Kogenate®
79. Laboratory identification of the lupus anticoagulant
80. Assays for detection of antiphospholipid antibodies
81. Criteria for the diagnosis of lupus anticoagulants: An update